Seite 1 von 60
Neuester Beitrag: 19.10.21 19:46
|Eröffnet am:||18.07.15 15:34||von: Cobra7||Anzahl Beiträge:||2.486|
|Neuester Beitrag:||19.10.21 19:46||von: St.Martin||Leser gesamt:||266.449|
|Seite: < 1 | 2 | 3 | 4 | 58 | 59 | 60 60 >|
hier eine sehr interessante Biotechaktie mit einer noch interessanteren Pipeline
RHB-105 - A combination therapy for Helicobacter pylori infection, with successful top-line results from a first Phase III study.
RHB-104 A combination therapy for the treatment of Crohns disease, with a phase III clinical study underway, and for multiple sclerosis, with a Phase IIa proof of concept study underway.
BEKINDA (RHB-102) A once-daily oral pill formulation of ondansetron, with a Phase III study underway in the U.S. for acute gastroenteritis and gastritis and a European marketing application for chemotherapy and radiotherapy-induced nausea and vomiting submitted to the UK MHRA in December 2014.
RHB-106 An encapsulated formulation for bowel preparation licensed to Salix Pharmaceuticals Ltd.
ABC294640 A Phase II-stage orally-administered SK2 inhibitor targeting multiple inflammatory-GI diseases and related oncology indications
MESUPRON® A Phase II uPA inhibitor, administered by oral capsule, targeting gastrointestinal and other solid tumor cancers.
RP101 A Phase II-stage Hsp27 inhibitor, administered by oral tablet, targeting pancreatic and other gastrointestinal cancers, currently subject to an option-to-acquire by RedHill.
RIZAPORT (RHB-103) An oral thin film formulation of rizatriptan, for the treatment of acute migraines, with a U.S. NDA under review by the FDA and a European marketing application submitted to the German BfArM in October 2014.
link für die Presentation:
link für die News: